ResMed shares are in a two-month lull. Is this a chance to buy?

ResMed shares are still trading below the price targets of several brokers.

| More on:
Exhausted young Caucasian woman lying on comfortable sofa in living room sleeping after hard-working day, tired millennial female fall asleep on couch at home, take nap or daydream, fatigue concept

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed CDI (ASX: RMD) shares are trading at $31.94 apiece on Friday, up 0.60% for the day and outpacing the ASX 200, which is up 0.17%.

ResMed stock is up 25.8% in the year to date but this includes a two-month lull over May and June so far.

During this period, the share price has been rangebound between about $31 and $33 per share.

This is well below the 12-month price target of several brokers.

So it begs the question, are ResMed shares a buy while they are stuck in the doldrums?

ResMed shares overcome last year's panicked sell-off

As the chart above shows, ResMed shares were sold off in the second half of last year.

The sleep apnoea device maker lost market capitalisation mainly because investors started feeling nervous about the potential impact of GLP-1 drugs like Ozempic on demand for ResMed's products.

They feared an impact because GLP-1 drugs are incredibly effective in treating obesity, and this disease is a common precursor to sleep apnoea.

That fear sent ResMed shares tumbling to a four-year low of $21.14 on 13 October.

But the stock has rebounded significantly after the company and many brokers educated investors.

The key messages included that sleep apnoea has many different causes — not just obesity.

Secondly, the total addressable market (TAM) remains enormous despite any impact GLP-1s might have on rates of obesity worldwide.

What ResMed told shares investors about GLP-1s

ResMed CEO Mick Farrell told investors last October that in-house modelling had quantified the impact of GLP-1s on ResMed's TAM.

He said GLP-1s may cost the company 200 million people in terms of TAM. However, the total TAM for sleep apnoea worldwide would still be 1.2 billion by 2050 after taking GLP-1s into account.

At the time, 22.5 million people were using ResMed CPAP machines. Thus, Farrell successfully demonstrated the small proportionality of the GLP-1 risk to ResMed's business.

Then in January, Farrell revealed further in-house research that found GLP-1s were actually bringing in more customers for ResMed.

The research showed a 10% increase in patients on GLP-1s buying sleep apnoea machines.

This is happening partly because the GLP-1 hype has encouraged people to see their doctor about their obesity for the first time. During these consultations, sleep apnoea has also been identified, leading to more people buying ResMed products.

Blackwattle Investment Partners reckon ResMed has actually "turned the GLP threat into an opportunity" by raising awareness of the combined healthcare benefits of GLP-1 drugs and CPAP products.

Brokers say it's not too late to buy

Bell Potter has a buy rating on ResMed shares and a 12-month price target of $36. Citi has the same rating and price target. Macquarie has an outperform rating on the stock with a $34.85 price target.

Based on these targets, ResMed shares have room for 10% to 13% more share price growth.

Lachlan Hughes, a portfolio manager at Swell Asset Management, says ResMed has "decades of growth ahead as the penetration is low and it's the number one player in its market".

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 66% in FY24, will Telix Pharmaceuticals shares continue?

After such an impressive run, has the trend exhausted?

Read more »

Man sleeping with a sleep apnoea mask on.
Healthcare Shares

Buy Resmed shares at 'attractive entry level' says top broker

Could this be the right entry point to own Resmed?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

CSL shares hit new 52-week high! What's next?

These ASX experts reckon CSL investors are still in for a treat.

Read more »

ASX share price movement represented by doctor pressing digitised screen with array of icons including one entitled health insurance,
Healthcare Shares

NIB shares rise as top broker calls the stock a buy

Is this stock a healthy opportunity?

Read more »

Man pointing at a blue rising share price graph.
Healthcare Shares

Why is the Nanosonics share price rocketing 10% today?

Investors are pleased with a big improvement in this company's performance.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why the ResMed share price tanked in FY 2024 and what to expect in FY 2025

Down 11% in FY 2024, is the ResMed share price poised for a big turnaround in FY 2025?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX healthcare stock rocketing 25% on Friday?

What is getting investors excited? Let's find out.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development
Record Highs

Why is the Telix Pharmaceuticals share price rocketing 15% to a record high?

Good news out of the United States is giving this radiopharmaceuticals stock a boost.

Read more »